MOUNTAIN VIEW, CA - VIVUS Inc. announced in a Tuesday press release that the European Patent Office has granted a patent for Qnexa, an investigational, oral weight loss product for the treatment of obesity and related conditions.
The European patent, No. 1,187,603, broadly covers Qnexa and its use as a weight loss treatment. The patent extends the Intellectual Property protection of Qnexa beyond the already issued patents in the United States and abroad.
"This patent represents another successful milestone for VIVUS. Qnexa is now protected by several issued patents and is the subject of multiple pending patent applications in the United States and other countries,” President and CEO of VIVUS Leland Wilson said.
“The grant of the European patent application significantly expands the Intellectual Property protection for Qnexa," he added.
The patent broadly covers methods and pharmaceutical compositions effecting weight loss with combinations of a sypathomimetic, including phentermine and an anticonvulsant, including topiramate.
The two active components in Qnexa are phentermine and topiramate. The patent includes a wide range of doses, timing and administration of the active components as well as packaging and titration kits expected to be used with Qnexa.
VIVUS Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products.
